Please sign in to follow a disease.
T-cell and NK-cell neoplasm
MONDO:0024615Also known as: T-cell and NK-cell neoplasm, T-cell neoplasm
2148 clinical trials for this condition and its sub-types, 8 tagged with T-cell and NK-cell neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of T-cell and NK-cell neoplasm
-
Neoplasm of mature T-cells or NK-cells 4 trials · 248 incl. sub-types
4 sub-types
- Mature T-cell and NK-cell non-Hodgkin lymphoma 150 trials · 240 incl. sub-types Sub-types →
- Peripheral T-cell lymphoma, not otherwise specified 61 trials
- EBV-positive T-cell lymphoproliferative disorder of childhood 3 trials · 7 incl. sub-types Sub-types →
- Chronic lymphoproliferative disorder of NK-cells 4 trials
-
T lymphoblastic leukemia/lymphoma 18 trials · 100 incl. sub-types
5 sub-types
- T-lymphoblastic lymphoma 32 trials
- Refractory precursor T-lymphoblastic lymphoma/leukemia 31 trials
- T-cell prolymphocytic leukemia 17 trials
- Childhood precursor T-lymphoblastic lymphoma/leukemia 0 trials · 13 incl. sub-types Sub-types →
- Aggressive NK-cell leukemia 11 trials
Most studied deeper sub-types
-
Experimental CAR-T therapy targets tough lymphoma in early trial
Disease control Recruiting nowThis early-phase study tests a new treatment called JV-394 for people with T/NK cell lymphoma that has come back or not responded to standard therapy. JV-394 is made from a patient's own immune cells, which are modified to attack cancer cells. The main goal is to find a safe dose…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare blood cancers: experimental drug ELA026 enters human testing
Disease control Recruiting nowThis early-stage study tests an experimental drug called ELA026 in adults with T/NK cell blood cancers that have come back or not responded to prior treatments. The main goals are to check the drug's safety and find the right dose. About 84 participants will be enrolled across mu…
Phase 1 • Sponsor: Electra Therapeutics Inc. • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New CAR T-Cell therapy takes aim at tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD5 CAR T-cells for people with T-cell cancers (like certain leukemias) that have returned or not responded to standard care. The treatment uses a patient's own immune cells or cells from a donor, which are modified in a lab to recognize an…
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for Tough-to-Treat T-Cell lymphoma? pacritinib trial opens
Disease control Recruiting nowThis study tests a drug called pacritinib in 100 people with T-cell lymphoma that has returned or not responded to prior therapy. The main goal is to see how many patients have their tumors shrink or disappear. Participants take the drug and are monitored with scans and skin asse…
Phase 2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Engineered immune cells take on tough T-Cell cancers
Disease control Recruiting nowThis study tests a new treatment called CD7 CAR T-cell therapy for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses a patient's own immune cells or cells from a donor, which are modified to find and attack cancer cells. The …
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Engineered immune cells take aim at tough T-Cell cancers
Disease control Recruiting nowThis study tests a new type of CAR T-cell therapy that targets a protein called CD5 on cancer cells. It is for people with T-cell cancers that have come back or not responded to standard treatments. The therapy uses the patient's own immune cells or cells from a donor, which are …
Phase 1/2 • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
AI and genes join forces to outsmart rare lymphoma
Knowledge-focused Recruiting nowThis study collects genetic data from 1,200 people with T-cell or NK-cell lymphoma to see if machine learning can predict who will respond to treatment. Researchers hope to find patterns that explain why some patients relapse or become resistant to therapy. The goal is to pave th…
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC